Robert E. Widdop

Clayton, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 80 publications

The AT2 receptor as a potential target for autosomal dominant polycystic kidney disease therapy?

The AT2 receptor as a potential target for autosomal dominant polycystic kidney disease therapy?

Journal: Expert opinion on therapeutic targets

Published: June 15, 2026

Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart disease.

Serelaxin has greater anti-fibrotic potential than perindopril but maintains its anti-fibrotic efficacy in the presence of perindopril in normotensive mouse models of heart disease.

Journal: Life sciences

Published: March 18, 2026

Investigational insights into the potential of angiotensin type II receptor agonists as therapeutics for idiopathic pulmonary fibrosis.

Investigational insights into the potential of angiotensin type II receptor agonists as therapeutics for idiopathic pulmonary fibrosis.

Journal: Expert opinion on investigational drugs

Published: January 12, 2026

Sex-dependent differences in the progression of renal injury and fibrosis following ischemic acute kidney injury.

Sex-dependent differences in the progression of renal injury and fibrosis following ischemic acute kidney injury.

Journal: Clinical science (London, England : 1979)

Published: October 26, 2025

Sex-dependent differences in the progression of renal injury and fibrosis following ischemic acute kidney injury.

Sex-dependent differences in the progression of renal injury and fibrosis following ischemic acute kidney injury.

Journal: Clinical science (London, England : 1979)

Published: October 26, 2025

Novel Mouse Model of Coronary Atherosclerosis With Myocardial Infarction: Insights Into Human CAD.

Novel Mouse Model of Coronary Atherosclerosis With Myocardial Infarction: Insights Into Human CAD.

Journal: Circulation research

Published: June 09, 2025

The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis.

The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis.

Journal: Clinical science (London, England : 1979)

Published: December 18, 2024

Transition from acute kidney injury to chronic kidney disease: mechanisms, models, and biomarkers.

Transition from acute kidney injury to chronic kidney disease: mechanisms, models, and biomarkers.

Journal: American journal of physiology. Renal physiology

Published: September 19, 2024

Novel angiotensin receptor target as therapy for the diabetic heart: the AT2R.

Novel angiotensin receptor target as therapy for the diabetic heart: the AT2R.

Journal: Journal of molecular and cellular cardiology

Published: September 15, 2024

Angiotensin-(1-9) Retro-Enantiomer Peptide With Cardioprotective Activity.

Angiotensin-(1-9) Retro-Enantiomer Peptide With Cardioprotective Activity.

Journal: Circulation

Published: September 03, 2024

The renoprotective efficacy and safety of genetically-engineered human bone marrow-derived mesenchymal stromal cells expressing anti-fibrotic cargo.

The renoprotective efficacy and safety of genetically-engineered human bone marrow-derived mesenchymal stromal cells expressing anti-fibrotic cargo.

Journal: Stem cell research & therapy

Published: August 06, 2024

Sex- and time-dependent role of insulin regulated aminopeptidase in lipopolysaccharide-induced inflammation.

Sex- and time-dependent role of insulin regulated aminopeptidase in lipopolysaccharide-induced inflammation.

Journal: Frontiers in immunology

Published: July 18, 2024

Showing 1-12 of 80

Last Updated: 09/26/2026